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Molecular information obtained from cancer patients’ blood is an emerging and powerful
research tool with immense potential as a companion diagnostic for patient stratification
and monitoring. Blood, which can be sampled routinely, provides a means of inferring the
current genetic status of patients’ tumours via analysis of circulating tumour cells (CTCs)
or circulating tumour DNA (ctDNA). However, accurate assessment of both CTCs and
ctDNA requires all blood cells to be maintained intact until samples are processed. This
dictates for ctDNA analysis EDTA blood samples must be processed with 4 h of draw,
severely limiting the use of ctDNA in multi-site trials. Here we describe a blood collection
protocol that is amenable for analysis of both CTCs and ctDNA up to four days after blood
collection. We demonstrate that yields of circulating free DNA (cfDNA) obtained from
whole blood CellSave samples are equivalent to those obtained from conventional EDTA
plasma processed within 4 h of blood draw. Targeted and genome-wide NGS revealed com-
parable DNA quality and resultant sequence information from cfDNA within CellSave and
EDTA samples. We also demonstrate that CTCs and ctDNA can be isolated from the same
patient blood sample, and give the same patterns of CNA enabling direct analysis of the ge-
netic status of patients’ tumours.
In summary, our results demonstrate the utility of a simple approach that enabling robust
molecular analysis of CTCs and cfDNA for genotype-directed therapies in multi-site clinical
trials and represent a significant methodological improvement for clinical benefit.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).DNA; CTC, circulating tumour cell; ctDNA, circulating cell-free tumour DNA; NGS, next gen-
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M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 5 6 6e5 7 4 5671. Introduction sample and enable a direct comparison of CTCs, that provideTechnological advances in blood borne cancer biomarkers
now make it possible to routinely analyse RNA and DNA
from single cells (Rothwell et al., 2014; Ramskold et al., 2012;
Guzvic et al., 2014) including isolated circulating tumour cells
(CTC)s and the minute amounts of tumour derived DNA
present in patient blood samples (reviewed in Krebs et al.,
2014; Diaz and Bardelli, 2014). Circulating cell-free DNA
(cfDNA) analysis is emerging as a relatively simple yet power-
ful biomarker for monitoring disease status and reporting
mechanisms of treatment resistance in cancer patients, with
the important advantage of being minimally invasive and
suitable for longitudinal sampling (Murtaza et al., 2013).
CTCs have also been shown to be clinically informative with
CTC enumeration recognised as a prognostic biomarker by
the FDA in metastatic breast, prostate and colorectal cancers
(Cristofanilli et al., 2004; de Bono et al., 2008; Cohen et al.,
2008). More recently, CTCs have been expanded in vitro and
in vivo providing valuable insights into tumour biology
(Hodgkinson et al., 2014) and have the potential to provide
a minimally invasive opportunity to study tumour genetic
profiles, drug resistance mechanisms and evaluate tumour
heterogeneity.
However, for accurate and sensitive analysis of both CTCs
and cfDNA, it is important to ensure that blood collection,
transport and processing do not result in cell damage or lysis
resulting in loss of CTCs or dilution of cfDNA by lysed white
blood cell (WBC) contents. Dilution of ctDNA due to WBC lysis
may hinder the ability to detect clinically important tumour
associated mutations, or lead to misleading estimates of
the mutant fraction of cfDNA, thereby impairing studies of
residual disease and emergent mechanisms of treatment
resistance (Luke et al., 2014; De Mattos-Arruda et al., 2013).
In standard cfDNA protocols, WBC lysis is minimized by prep-
aration of plasma within a short time from the blood
draw (typically 1e4 h), which may be challenging in
non-specialized sites and busy clinics. This requirement for
immediate processing of the blood sample severely limits
the scope of the use of cfDNA in a larger clinical setting,
including genotype-directed multi-centre clinical trials where
samples need to be shipped to central laboratories. Recently,
the use of dedicated blood collection tubes containing a pre-
servative which allows transport of whole blood at ambient
temperature for several days prior to cfDNA isolation has
been shown to extend the window within which samples
can be used for cfDNA extraction (Norton et al., 2013). For
CTC analysis, the gradual loss of cell integrity with prolonged
storage of a standard EDTA blood sample is overcome by using
a CellSearch CellSave Preservation tube. This preserves cells
in whole blood for up to 4 days at room temperature and
allows international transport of blood samples and a stand-
ardised workflow without the need for sample processing at
collection sites. Using the CellSearch CellSave system, CTCs
can be fluorescently labelled and enumerated (Hou et al.,
2012), and isolated and genetically characterized by whole
genome sequencing (WGS) (Hodgkinson et al., 2014). Analysis
of CTCs and cfDNA from the same whole blood sample would
extend the molecular information extracted from a singleinformation at the single cell level and cfDNA, which repre-
sents a global molecular picture of the disease (Kidess and
Jeffrey, 2013). Here, we describe the isolation of CTCs and
cfDNA from CellSave blood samples, followed by genome-
wide and focused next generation sequencing (NGS) to
establish reliable and effective analysis of both CTCs and
cfDNA from whole blood transported up to 4 days at ambient
temperature. This potentially enables non-specialized clinical
sites to ship blood samples to central laboratories for expert
processing and analysis, reducing the time required for blood
processing in busy clinics, minimizing variability in the resul-
tant molecular data obtained and opening molecular analysis
of CTCs and cfDNA to large multi-centre clinical trials.2. Material and methods
2.1. Healthy normal volunteer (HNV) and patient blood
sample collection
Paired blood samples were collected in a CellSave and an
EDTA vacutainer and transferred to the Clinical and Experi-
mental laboratory for processing. All samples were collected
either from HNVs (persons recruited from within the CR-UK
Manchester Institute that were not currently suffering or
being treated for cancer) or cancer patients following receipt
of informed consent in compliance with the Declaration
of Helsinki under ethics 07/H1014/96 after approval from the
Internal Review and the Ethics Boards of the Christie Hospital
NHS Trust. Throughout the study a total of 20 HNV, 11 small
cell lung cancer (SCLC) and 34 melanoma patients were
recruited and cfDNA isolated.
2.2. cfDNA preparation and quantification
For both EDTA and CellSave blood samples plasma was sepa-
rated from whole blood by means of two sequential centrifu-
gations (2,000 g, 10 min) and stored at 80 C in 1 ml
aliquots. cfDNAwas isolated from 1ml of double spun plasma
using the QIAamp Circulating Nucleic Acid Kit (Qiagen) as per
manufacturer’s instructions. Following isolation the cfDNA
yield was quantified using the TaqMan RNase P Detection
Kit (Life Technologies) as per manufacturer’s instructions.
2.3. Enrichment and isolation of CTCs
CTCs and WBCs (pre-stained with antibody to CD45, pan-CK
and DAPI) were aspirated from the CellSearch cartridge used
for the CTC enumeration, and single cells were isolated
using the DEPArray system (Silicon Biosystems) as per manu-
facturer’s instructions. WGA of single CTCs and WBCs was
performed using the Ampli1 WGA kit (Silicon Biosystems)
according to manufacturer’s instructions.
2.4. NGS library preparation and sequencing
Whole genome sequencing (WGS) of CTC derived explant tu-
mours (CDX), CTCs and WBCs was carried out as previously
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with a minimum of 8 ng cfDNA was performed using the
Qiagen GeneRead Lung Cancer v1 Panel (Qiagen) as described
by the manufacturer, except input was reduced to as low as
8 ng DNA (ensuring 2 ng input into each of the 4 Qiagen
GeneRead multiplex PCR reactions). This panel covered 20
genes commonly mutated in lung cancer (MTOR, NRAS,
PTGS2, PTEN, HRAS, KRAS, RB1, AKT1, TP53, ERBB2, STK11,
ALK, CTNNB1, PIK3CA, PDGFRA, KIT, EGFR, MET, BRAF,
CDKN2A). WGS of cfDNA was carried out using the NEBNext
Ultra DNA Library Prep Kit for Illumina kit (NEB) using 5 ng
DNA input. NGS for both focused GeneRead libraries andWGS
cfDNA libraries was carried out using an Illumina MiSeq
desktop sequencer.
2.5. Targeted NGS analysis
Analysis of the GeneReadNGS data was performed on the Qia-
gen Cloud-Based DNAseq Sequence Variant Analysis software
according to the manufacturer’s instructions. For WGS, anal-
ysis paired-end sequence reads were aligned to the human
reference genome GRCh37/hg19 using the BurrowseWheeler
alignment tool (BWA, version 0.7.4) with default parameters
and the BWA-MEM algorithm. The alignments were sorted
and indexed by chromosome coordinates using SAMtools
(version 0.1.19), followed by PCR duplicates removal using Pic-
ard tools MarkDuplicates function (version 1.96) (http://pic-
ard.sourceforge.net). Single nucleotide variants (SNVs) were
identified using VarScan2 (version 2.3.7) with the following
settings: min-coverage ¼ 8, min-reads2 ¼ 2, min-
avg.qual ¼ 15, min-var-freq ¼ 0.01, p-value ¼ 0.01.
2.6. Copy number aberration analysis from WGS data
Paired-end sequence reads were aligned to the human refer-
ence genome GRCh37/hg19 using SMALT aligner (version
0.7.1, http://www.sanger.ac.uk/resources/software/smalt/).
SMALT index was built by setting k ¼ 20 and s ¼ 13. The align-
ments were sorted and indexed by chromosome coordinates
using SAMtools (version 0.1.18). Copy number variations
were predicted by using Control-FREEC(version 6.4) with the
following settings: coefficientOfVariation ¼ 0.1, ploidy ¼ 2,
mateOrientation ¼ FR. Control-FREEC produces different
window sizes according to the sequencing depth in each
sample. In order to cluster the samples by their copy number
profiles, we decomposed the overlapping windows into
disjoint (i.e. non-overlapping) windows. The newly formed
bins inherited the copy number status that was assigned to
its parental window before decomposition. After this opera-
tion, we obtained a matrix with equal number of bins across
samples. Then the samples were hierarchically clustered by
their copy number profiles based on the Euclidian distance
and the Ward linkage method in R.
2.7. Evaluation of NGS error rates
Two metrics were used to infer mutation rate in the CellSave
and EDTA samples: the first was calculated as the number of
SNV detected divided by total number of bases in the pileup
file; the second metric was calculated by dividing the numberof SNV detected by number of bases with at least 8 coverage
in the pileup file.
To account for variation in sequencing depth between
samples, we performed 100 down-sampling of the aligned
data, keeping 1 million read pairs in each iteration. We
re-calculated the mutation rates by averaging the output
from all iterations. A two-tailed t-test was performed to assess
if the mutation rate is significantly different between CellSave
and EDTA samples.3. Results
3.1. Isolation of cfDNA from EDTA and CellSave HNV
blood samples
Our objective was to evaluate the ‘real life’ utility of CellSave
preserved whole blood collection for analysis of cfDNA and
CTCs as applied to blood samples obtained in multiple sites
and shipped to a centralised laboratory for analysis. This
had the wider goal of developing a standardised protocol to
facilitate the generation of consistent, molecular analysis of
both cfDNA and CTCs in clinical samples. To determine the
effect of WBC lysis on cfDNA yields following long term
storage (>24 h) of whole blood in EDTA, we isolated plasma
from blood within 1 h of collection in a standard EDTA
vacutainers tube and then at 24, 48, 72 and 96 h post-draw.
Following isolation, the cfDNA yield was determined using
the RNAseP real-time PCR assay (Figure 1A). Increasing
amounts of cfDNA were detected over time, with almost a
3-fold increase seen by 24-h post-draw, increasing to over
60 fold by 96 h, which could reduce the ability to detect the
ctDNA fraction within clinical samples.
To evaluate the suitability of using CellSave to reduceWBC
lysis and facilitate cfDNA analysis, we undertook a 20 healthy
normal volunteers (HNV) study where each HNV donated two
EDTA and two CellSave blood samples. For each HNV donor
cfDNA was isolated from one EDTA and one CellSave tube
within 4 h post blood draw (isolation range 2.0e3.3 h,
mean ¼ 2.8 h). The remaining EDTA and CellSave tubes were
sent through the British postal system back to the host insti-
tute using a Royal Mail Safe Box, thenmaintained at ambient
temperature storage for up to 96 h post-draw (isolation range
93.3e95.3 h, mean ¼ 94.5 h) (Figure 1B). The yield of cfDNA
from all samples was determined using an RNAseP real-time
PCR assay, and showed no significance difference between
the 4 h EDTA, 4 h CellSave and 96 h CellSave samples
(Figure 1C). As expected, a significant increase in cfDNA was
seen in the 96 h EDTA sample compared to both the CellSave
samples and the 4 h EDTA sample, reflecting extensive WBC
lysis.
3.2. Evaluation of EDTA and CellSave cfDNA NGS error
rates
Although the CellSave preservative significantly reduced the
level of WBC lysis, thereby maintaining the ctDNA fraction
within samples, it is possible that the components of the
CellSave tube could act as a DNA damaging agent and effec-
tively increase background sequencing errors. To test this,
Figure 1 e A. Graph showing increase in cfDNA levels in plasma from EDTA blood left at room temperature for up to 96 h post-draw.
B. Schematic of EDTA and CellSave cfDNA stability study. C. cfDNA yields from 20 HNV blood samples collected in EDTA or CellSave and
processed either 4 h or 96 h post-draw. No significant difference in overall yields between the 4 h EDTA, 4 h CellSave and 96 h CellSave samples
with a highly significant increase in cfDNA yield following 96 h in EDTA.
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HNVwere subjected toWGS. To estimate the overall mutation
burden low pass WGS Illumina MiSeq sequencing data were
generated from three technical replicates of each sample
set, with pooled cfDNAof each sample set being used to obtain
the 5 ng cfDNA input. Over 1.0  108 bases were sequenced for
each library with approximately 9.5  103 single nucleotide
variants (SNVs) identified per sample when analysed against
the Hg19 genome. No significant difference was found be-
tween the overall quality of the NGS data in terms of overall
coverage, mapability, duplicates and total reads, and muta-
tion rates of the CellSave (60.4 SNV per million bases)
compared to the EDTA samples (58.9 SNV per million bases)
indicating CellSave cfDNA is compatible with extended NGS
strategies (Figure 2A and 2C). Analysis of the types of SNVdetected within the cfDNA in each collection tubes was also
performed, with similar frequencies of transitions and trans-
versions seen in both sample type suggesting no effect of Cell-
Save preservative on cfDNA integrity (Figure 2B).
3.3. Isolation of cfDNA from EDTA and CellSave patient
blood samples
CellSave vacutainers are routinely used for CTC enumeration
using the CellSearch platform and molecular analysis of
CTCs retrieved from CellSearch cartridges can be achieved
using both focused and genome wide NGS (Hodgkinson
et al., 2014; Gasch et al., 2013; Heitzer et al., 2013). Since the
CellSearch system requires 7.5 ml blood input and the Cell-
Save vacutainer can hold up to 10 ml there is often surplus
Figure 2 e A. Number of single nucleotide variations identified in a pool of HNV cfDNA prepared from either EDTA processed up to 4 h post
blood draw and CellSave processed 96 h post blood draw. There was no significant difference in SNPs per million bases for the EDTA and
CellSave cfDNA samples (paired t-test p> 0.05). B. Repertoire of mutations detected in each collection with equal frequencies of transitions and
transversions seen in both EDTA and CellSave samples. C. Summary of overall quality of NGS data generated from EDTA and CellSave derived
cfDNA showing comparable levels of mapping, read alignment and duplication.
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suitability of CellSave for cfDNA analysis of clinical samples,
we compared yields of cfDNA obtained from surplus CellSave
blood to yields of cfDNA obtained from sample obtained from
a parallel EDTA blood sample processed to plasma within 4 h
from two clinical cohorts. Analysis of 11 SCLC and 34 mela-
noma patient samples showed comparable yields of patient
cfDNA from 4 h EDTA plasma (hereafter referred to as stan-
dard EDTA) to cfDNA isolated from CellSave blood kept at
room temperature for up to 96 h (Figure 3A). This mirrored
the results from the HNV experiment and showed CellSave
blood to be stable source of both cfDNA and CTCs for clinical
sample analysis.3.4. Targeted NGS of EDTA and CellSave cfDNA
With the drive to utilise cfDNA to identify disease-associated
mutations we next tested the suitability of CellSave cfDNA
for targeted NGS analysis of clinical samples. To this end, 5
of the 11 SCLC patients with above 8 ng of cfDNA available
for both standard EDTA and CellSave cfDNAs were analysed
using the Qiagen GeneRead Lung Cancer Panel. This panel
consists of 4 pools of PCR-based amplicons that covers 20
lung cancer associated genes. Analysis of the NGS data was
carried out and compared to a corresponding germline sample
from each patient for each EDTA and CellSave sample. In
keeping with the high frequency of TP53 mutations in SCLC(Peifer et al., 2012; Rudin et al., 2012; George et al., 2015),
somatic TP53 mutations were identified in 4 of the 5 SCLC
patients analysed with essentially identical results observed
for both EDTA and CellSave matched samples (Figure 3B).
For 1 patient (SCLC-03) who did not harbour a detectable
TP53 mutation, an ALK mutation was detected, again with
similar levels seen for both EDTA and CellSave matched sam-
ples. For patient SCLC-05, in addition to a TP53 mutation, a
second lower frequency mutation in ERBB2 was also consis-
tently identified in both EDTA and CellSave samples suggest-
ing possible tumour heterogeneity within this patient.3.5. Whole genome copy number alteration (CNA) of
matched cfDNA and CTCs
As well as the identification of tumour associated mutations,
low depth whole genome sequencing (WGS) of cfDNA can be
used to characterise CNA patterns arising from the circulating
tumour DNA (ctDNA) present in the total cfDNA (Leary et al.,
2012; Mohan et al., 2014). Since we and others have shown
CNA analysis can be readily applied to CTCs isolated following
CellSearch enrichment (Hodgkinson et al., 2014; Gasch et al.,
2013; Heitzer et al., 2013), use of CellSave for cfDNA isolation
would enable combined CTC and cfDNA analysis from
the same collection tube (Figure 4A), thereby maximizing the
potential clinical information that can be elucidated.
Figure 3 e A. Yields of cfDNA from duplicate clinical samples collected in EDTA and CellSave bloods from a cohort of 11 SCLC and 34
melanoma patients. No significant difference was found between each collection type in both cohorts. B. Mutations identified in five SCLC patient
samples using a targeted NGS approach. Germline gDNA, EDTA cfDNA and CellSave cfDNA was analysed for each patient. Mutations were
called with read counts>200 and frequency>10%. Mutated samples are indicated by red fill with WT alleles indicated by green fill.
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CellSave whole blood sample was used for CTC isolation via
CellSearch and DEParray as previously described
(Hodgkinson et al., 2014) and the remaining CellSave blood
(typically 1e2.5 ml) was used to prepare cfDNA. WBCs were
used as a germline control for CTC CNA analysis and WGS of
whole blood DNA served as a germline control for the cfDNA
samples. For one patient, we were also able to generate CDX
tumours in an immune-compromised mouse following CTC
enrichment of a parallel EDTA blood sample. We have previ-
ously shown that these enriched CTCs can give rise to Circu-
lating tumour cell Derived Xenografts (CDX tumours) that
provide tumourmaterial (Hodgkinson et al., 2014), to compare
CNA patterns from both CTCs and cfDNA obtained from the
corresponding CellSave blood sample. Figure 4 shows the
comparison of CNA profiles generated from isolated CTCs,
EDTA cfDNA, CellSave cfDNA, two CDX tumours, germline
gDNA and isolated WBC DNA from 2 SCLC patients. Theresults show a clear tumour related CNA patterns in matched
CTC, CDX and cfDNA with similar patterns seen for both Cell-
Save and EDTA cfDNA. The pattern of gain and loss in the two
CDX tumours in patient 1 (Figure 4B) are consistent with pre-
viously published studies on CNA in SCLC (Peifer et al., 2012;
Rudin et al., 2012) with regions containing RASSF1 and FHIT
being lost and regions containing SOX2 and BCL2 showing
amplification. The CDX tumours also show amplification of
regions of chromosomes 2 and 14, with this pattern also
observed in both CTCs and all cfDNA samples. In patient 2
(Figure 4C) there was no CDX tumour available, but regions
of loss and gain in the CTCs correspond well with published
data, including loss of chromosome 17 (TP53) and amplifica-
tion of chromosome 3 (SOX2). A similar pattern of loss and
gain is also seen in the CNA of the cfDNA samples, with
good correlation between the EDTA and CellSave samples
showing CellSave cfDNA to be suitable for NGS CNA and
compatible with combined CTC collection and analysis.
Figure 4 e A. Schematic showing procedure for processing of a single blood sample to give NGS analysis of cfDNA and CTCs. B & C.
Unsupervised, hierarchical clustering of CNA profiles in two SCLC patients. CNA profiles were generated from isolated CTCs, EDTA cfDNA,
CellSave cfDNA, two CDX tumours (A only), germline gDNA and isolated WBC. Matching patterns of gain (regions of red) and loss (regions of
blue) were seen across all tumour material and were absent from germline controls. Arrows indicate location of common copy number aberrations
found in SCLC with red indicating gain and blue loss. Dark filled arrows indicate loci altered in the patient sample.
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The utilisation of blood borne biomarkers such as ctDNA and
CTCs for the molecular profiling of tumours and longitudinal
sampling has immense clinical potential that is starting to
be realised (Murtaza et al., 2013; Garcia-Murillas et al., 2015).
However, to fully realise this potential it is important that
the biomarkers are applicable to multi-centre studies and
accurately represent the molecular status of the tumour at
the time of collection. In an attempt to ensure this we have
evaluated the use of preserved CellSave whole blood as a
source of both CTCs and cfDNA.
Initial experiments looking at cfDNA yields from CellSave
bloods were consistent with both an effective reduction in
WBC lysis and efficient cfDNA isolation fromwhole blood Cell-
Save samples kept at ambient temperature for up to 96 h. In
addition, WGS NGS analysis of overall mutational burden
following storage in CellSave showed no significant difference
to the 4 h EDTA sample. Both of these results suggest that
CellSave whole blood is a viable source of cfDNA.
Targeted NGS of matched EDTA and CellSave patient
cfDNA samples in 5 SCLC patients identified the same
mutations with similar tumour allele frequencies supporting
the suitability of CellSave whole blood collection for cfDNA
molecular analysis of clinical samples. Tumour specific
mutations were identified in both EDTA and CellSave isolated
ctDNA, with TP53 mutations, which are commonly associated
with SCLC, seen in 4 of the 5 patients. An ALK mutation
was identified in both the EDTA and CellSave ctDNA in the
remaining patient. Although ALK mutations at this locus
have not been previously reported, low frequency ALK trans-
locations have been observed in SCLC (Toyokawa et al., 2013)
raising the possibility that the detected mutation is involved
in the pathology of the disease.
Amajor benefit of CellSave blood is that it enables the anal-
ysis of both CTCs and cfDNA from the same tube. CTC analysis
provides molecular analysis of the tumour at the single cell
level and has the potential to give insight into tumour hetero-
geneity and EMT and mechanisms of metastatic spread of
the disease. ctDNA analysis provides a global picture of the
genetic status of the disease with ctDNA being released from
all disease sites enabling possible longitudinal detection of
tumour evolution and resistance mechanisms. This analysis
is interesting as it enables direct comparison of the two as
potential liquid biopsies and allows an evaluation of the
importance of determiningwhether genetic alterations picked
up by ctDNA assessment are co-expressed in single CTCs.
In summary, we have demonstrated the suitability of
whole blood CellSave samples for both CTC and cfDNAmolec-
ular analysis. The ability to generate informative molecular
profiles of both CTCs and cfDNA from a simple whole blood
sample shipped at ambient temperature for up to 4 days
represents a significant methodological improvement for
clinical benefit. The ability to process samples at a single
recipient site avoids site-to-site variability, a major confound-
ing issue in cfDNA analysis (Gormally et al., 2004, 2007).
Furthermore, the use of a simple blood collection protocol
does not require specialised equipment, such as centrifuges
or even refrigeration, extending the number of clinical sitesthat can participate in patient evaluation via liquid biopsies
to anywhere where a blood draw is taken. For example,
following initial cancer therapy, patients in remission can
be monitored via a blood draw at a local medical practice
rather than necessitating often lengthy/expensive trips to a
specialised oncology centre.
In September 2015, the first ctDNA companion diagnostic
assessing EGFR mutation for patient stratification was
approved by the EDA (Douillard et al., 2014). We posit that as
minimally invasive, liquid biopsies become increasingly
employed for cancer patient management, the ability to
routinely and simply draw blood and ship samples to
accredited biomarker assessment laboratories will facilitate
the dawn of this new development in the delivery of personal-
ised cancer medicines.Conflicts of interest
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